McKesson raises, narrows FY25 adjusted EPS view to $32.55-$32.95 from $32.40-$33

Consensus $32.67. CEO Brian Tyler said: “We remain committed to our enterprise growth strategy, including our growth pillars within oncology and biopharma services. This strategy has enabled our strong results and is a foundation for balanced growth and value creation. Based on our third quarter performance, we are raising and narrowing our guidance range for fiscal 2025 Adjusted Earnings per Diluted Share to $32.55 to $32.95. We are also pleased to announce the signing of a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, in support of our leadership in community practice management and specialty solutions. With this transaction, we intend to develop a leading platform for retinal care, delivering differentiated solutions and value across providers, biopharma partners, and patients. McKesson (MCK) has a long track record of leading practice management and clinical research outcomes with our differentiated Oncology platform, and we are excited to leverage this expertise to serve the high-growth area of retina and ophthalmology. We are executing against our strategy and expanding our suite of solutions to continue to pursue our purpose of advancing health outcomes for all.”